A1 Refereed original research article in a scientific journal

Molecular Characterization of Extracellular Vesicles From Human B Cell Lymphomas: Methodological Comparison to Vesicles From Patient Serum




AuthorsBadal, Md Nasir Uddin; Koivula, Tiia; Islam, Md Khirul; Lehtinen, Laura; Kauko, Otto; Leivo, Janne; Heinonen, Ilkka; Hämälistö, Saara

PublisherWiley

Publication year2026

Journal: Journal of Extracellular Biology

Article numbere70107

Volume5

Issue2

eISSN2768-2811

DOIhttps://doi.org/10.1002/jex2.70107

Publication's open availability at the time of reportingOpen Access

Publication channel's open availability Open Access publication channel

Web address https://doi.org/10.1002/jex2.70107

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/515667888

Self-archived copy's licenceCC BY

Self-archived copy's versionPublisher`s PDF


Abstract
Human B cell lymphomas represent a clinically heterogeneous disease group with lack of liquid biomarkers for specific subtype classification. Extracellular vesicles (EVs) hold promises as non-invasive biomarkers, yet their subtype-specific characteristics and clinical utility in these diseases remain largely underexplored. In this study, we have investigated the basic molecular and physical features of EVs from diffuse large B cell lymphoma (DLBCL) cells and from lymphoma patients’ serum. Data from e.g., electron microscopy (EM), Western blotting (WB), immunoassay and mass spectrometry (MS) revealed that the two main DLBCL cell subtype EVs differ in protein expression profile and in overall EV size, with the ABC (Activated B Cell) type having smaller EVs than the GCB (Germinal Centre B cell) type. The ABC type EVs were found significantly more enriched with tetraspanins CD81 and CD9. Parallel experimentation on lymphoma serum EVs revealed shared markers with lymphoma cell line EVs, and that B cell specific marker CD19 can be detected among other serum EVs. Also, to successfully detect markers, e.g. Hsp70 or CD44, in serum EVs we demonstrated to require more intense sample preparation in specific assays. While more patient studies are needed in the future, this pilot study paves the way for understanding the molecular differences in the DLBCL subtypes and for detecting them in the lymphoma EVs.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
This study was funded by the Research Council of Finland fundings 355957 (S.H.) and 324243 (I.H., T.K.) and the iCANDOC (N.B.; The Finnish National Doctoral Education Pilot in Precision Cancer Medicine) at the University of Turku. Open access publishing facilitated by Turun yliopisto, as part of the Wiley - FinELib agreement.


Last updated on 10/03/2026 08:08:29 AM